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Note: the CAEIP uses the conclusions of the systematic review to write this report, the contents of which is the 
responsibility of the authors. 
Note on the review: the validity of the statements in this report is subject to the possible variations in the 
effectiveness and/or costs shown by the clinical evidence and the studies made available after the date of 
publication of this report. The CAEIP shall, at least every 2 years, review this report according to the emergence 
of newly available evidence. 
 
Report by the Comissió d’Avaluació Econòmica i Impacte 
Pressupostari, CAEIP (Economic Evaluation and Budget Impact 
Commission), of Catsalut, on proton pump inhibitor drugs (PPIs) 
marketed in Spain1 
 
The systematic review of the economic evaluations of the different PPI active principles 
marketed in Spain shows, according to the authors, that: 
 
 Omeprazole is the PPI with the best pharmacoeconomic profile and should be used 
as the first choice. 
 
 No arguments were found, from the perspective of the cost-effectiveness analysis, 
for the use of a PPI other than omeprazole. In most of the indications, this 
conclusion is due to the fact that there is no evidence to suggest that the more 
expensive PPIs are more effective. 
 
 The only case that may lead to uncertainty is the treatment of severe 
gastroesophageal reflux disease (GERD) with esomeprazole which, in the doses 
used in the trials2, showed this PPI to be slightly superior to the rest, including 
omeprazole. This conclusion is preliminary and needs to be confirmed through 
empirical studies. Likewise, analyses of subgroups need to be carried out according 
to the severity of the GERD. 
 
 
In view of the systematic review and the available evidence, the CAEIP considers: 
 
 The preferential use of the active principle omeprazole for the treatments of GERD, 
peptic ulcers, ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs), 
the prevention of ulcers caused by NSAIDs and the eradication of Helicobacter 
pylori, since this active principle has shown the same effectiveness and a lower 
cost compared to the remaining active principles of its group. 
 
 That the greater efficiency of omeprazole should not, in any case, imply the 
exclusion of the selection of other alternatives which could, in specific cases, lead 
to improvements in terms of health due to any reason that causes a greater 
effectiveness of the treatment. 
 
 
Barcelona, 30 January 2007 
                                                 
1 esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole 
2 esomeprazole 40 mg; omeprazole 20 mg 
 
